11 Feb 2025
Eicher Motors
BOB Capital Markets Ltd.
Target
5333.50
5079.00
4972.35
(7.26%)
Target met
Hold
Broker Report
Q3 revenue increased ~21%/17% YoY/QoQ to Rs 42.1bn, driven by a mix of volume and realisation gain in the motorcycle segment
11 Feb 2025
Escorts Kubota
BOB Capital Markets Ltd.
Target
3321.70
2533.00
3129.70
(6.13%)
23.74
Sell
Broker Report
Q3 tractors volume rose by 25% YoY (combined volume from JV partners) aided by industry growth, realisation fell 13%
10 Feb 2025
Finolex Industries
BOB Capital Markets Ltd.
Reco
Target
218.16
250.00
195.01
(11.87%)
14.59
Buy
Broker Report
Gained market share in pipe segment in a difficult environment by offering heavy discounts to its dealers
09 Feb 2025
JK Lakshmi Cement
BOB Capital Markets Ltd.
Target
846.85
694.00
843.60
(0.39%)
Target met
Sell
Broker Report
Double-digit revenue decline YoY by 13% dragged by lower volume growth, down 5%, and weak realisations that fell by 10%
08 Feb 2025
Mahindra & Mahindra
BOB Capital Markets Ltd.
Target
2976.80
3689.00
3198.45
(-6.93%)
23.93
Buy
Broker Report
Automotive and tractor segment volume grew in double digits by ~16% /20% YoY; reflects strong show in festive/post-festive season
08 Feb 2025
The Ramco Cements
BOB Capital Markets Ltd.
Target
975.95
722.00
894.80
(9.07%)
26.02
Sell
Broker Report
Q3 revenue declined ~6%/3% YoY/QoQ as pricing pressures impacted realisations and profitability severely (down by 10%/5% YoY/QoQ)
08 Feb 2025
Life Insurance Corp
BOB Capital Markets Ltd.
Target
954.45
1071.00
816.10
(16.95%)
12.21
Buy
Broker Report
APE and net premium income declined 24% YoY and 11% YoY; renewal premium rose 4% YoY in Q3FY25
08 Feb 2025
Britannia Industries
BOB Capital Markets Ltd.
Reco
Target
5510.50
4395.00
4870.50
(13.14%)
20.24
Sell
Broker Report
Compared to consensus, there was a beat on sales at 1% and on EBITDA at 6%. EBITDA beat on lower SG&A as a % of sales
08 Feb 2025
Firstsource Solutions
BOB Capital Markets Ltd.
371.45
411.00
354.55
(4.77%)
10.65
Buy
Broker Report
3QFY25 broadly in line. Estimate organic growth in FY25 is likely at ~16% CC terms. Possibly second best in the Tierr-2 set
08 Feb 2025
Alkem Laboratories
BOB Capital Markets Ltd.
Reco
Target
5098.50
4527.00
5151.35
(-1.03%)
Target met
Sell
Broker Report
Domestic sales were 6% below our estimates mainly due to slower recovery in the acute therapies and no price hike in NLEM portfolio